Short Interest in Genmab A/S (OTCMKTS:GNMSF) Declines By 50.8%

Genmab A/S (OTCMKTS:GNMSF) saw a large decline in short interest in the month of September. As of September 30th, there was short interest totalling 104,900 shares, a decline of 50.8% from the September 15th total of 213,000 shares. Based on an average daily trading volume, of 1,300 shares, the short-interest ratio is presently 80.7 days.

Genmab A/S Stock Up 2.1 %

Shares of GNMSF stock traded up $5.00 on Friday, reaching $239.27. 1,189 shares of the stock were exchanged, compared to its average volume of 1,203. The firm has a 50 day moving average of $258.23 and a two-hundred day moving average of $270.51. Genmab A/S has a 1-year low of $226.00 and a 1-year high of $336.30. The stock has a market cap of $15.64 billion, a P/E ratio of 19.81 and a beta of 1.06.

Genmab A/S (OTCMKTS:GNMSF) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.13 earnings per share (EPS) for the quarter. The firm had revenue of $779.50 million during the quarter. Genmab A/S had a net margin of 29.06% and a return on equity of 20.60%.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.